Gufic Biosciences Limited (GUFICBIO.NS)

Gufic Biosciences Limited (GUFICBIO.NS) — VMCI valuation read

Headline read on GUFICBIO.NS: VMCI of 45/100 versus a Healthcare sector median of 50. The 5-point below-median position is what makes Gufic Biosciences Limited a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on GUFICBIO.NS: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on GUFICBIO.NS: value (GUFICBIO.NS trades at 25.0x earnings, 39% above the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 1.9x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

GUFICBIO.NS rose 2.7% over the trailing 7 days, with a -9.5% read on a 30-day basis.